SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) is trending due to a massive surge following news of a $250 million private placement to launch a Worldcoin treasury strategy. Community members are discussing potential short squeezes, comparing it to previous high-flying stocks, and debating whether the valuation is justified given the company's plans and the volatility of crypto-related investments, with some expressing concerns about a potential pump and dump.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following news of a multi-billion dollar AI infrastructure deal with Microsoft, significantly exceeding the company's current market cap and revenue projections. The community is discussing the potential for substantial revenue growth and future partnerships, while some caution against potential short-term volatility. This deal underscores the increasing importance of AI infrastructure and positions NBIS as a key player in the sector.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending as community members debate the influence of known short sellers, like Martin Shkreli and Citron Research, on the stock. Some traders are dismissing the impact of these short positions, citing upcoming catalysts such as potential interest rate cuts and new business developments for Opendoor. The discussion also includes speculation about a potential short squeeze and the company's long-term prospects in the evolving real estate market.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as the community discusses its potential linked to Sam Altman's ventures and its role in AI-driven identity verification, with some speculating on future partnerships. Community members are actively debating price targets and whether it can distinguish itself from other crypto projects. However, others express concerns over its tokenomics, limited utility, and privacy implications related to its iris-scanning technology.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position as the top meme coin on the Bitcoin network, emphasizing its fair launch and strong community. Many see it as a way to bring new users to the Bitcoin ecosystem and are actively discussing its potential to outperform other meme coins. The conversation highlights its unique status as a Bitcoin-native meme with a decentralized and community-driven approach.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Fangdd Network Group Ltd. is an investment holding company, which engages in the provision of real estate information services through its online platform. It also offers integrated marketing services for individual customers, real estate developers, and agents. The company was founded by Yi Duan, Xi Zeng, and Jian Cheng Li in October 2011 and is headquartered in Shenzhen, China.

Fangdd Network Group Ltd - Ordinary Shares - Class A

Fangdd Network Group

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

Hello Group, Inc. operates as a mobile-based social networking platform. It operates under the following segments: Momo's service lines, Tantan's service lines, and QOOL's service line. The company was founded by Yan Tang, Yong Li, Xiao Liang Lei and Zhiwei Li in July 2011 and is headquartered in Beijing, China.

Hello Group Inc - ADR

Momo

Toilet Dust ($TOILET) is a meme coin created on the Sui blockchain, designed to add some humor and chaos to the crypto world while playing a key role in driving the growth and adoption of the Sui ecosystem. Unlike typical meme coins that focus solely on entertainment or speculation, $TOILET’s mission goes beyond just the jokes. It is committed to fostering a vibrant, active community that’s passionate about both crypto and fun, while encouraging new users to explore the Sui blockchain.  The project’s foundation is built on the idea that a thriving network benefits everyone—whether you're a crypto enthusiast, developer, or investor. By embracing the lighthearted and unpredictable nature of meme coins, $TOILET brings attention to the Sui ecosystem and attracts a diverse range of participants. As $TOILET grows, so does the network and its ecosystem, creating more opportunities for everyone involved.  In addition to just memes, $TOILET is actively working on expanding its presence across social media, building partnerships, and increasing its visibility in the crypto space. It’s about creating an inclusive environment where the community drives the project forward. So, whether you're in it for the laughs, the community, or the chance to be part of something new, Toilet Dust is here to make a splash—join the movement or get left behind!

Toilet Dust

Toilet Dust ($TOILET.X) is trending as community members discuss accumulating the memecoin, emphasizing its potential within the SUI ecosystem; some users point to upcoming catalysts, including partnerships and NFT mints, while others express concerns about price action and past performance; overall sentiment seems mixed, with active discussions about team developments and future prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics, Inc. (PTCT) said on Tuesday that the U.S. Food and Drug Administration refused to approve its application for Vatiquinone for the treatment of children and adults living with Friedreich's ataxia.CEO Matthew B. Klein said that the company is disappointed by the FDA’s decision and plans to meet with the agency to discuss potential steps to address the issues flagged in its complete response letter to the company.In its <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-complete-response-letter-vatiquinone">letter</a>, the FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission. Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disease that primarily affects the nervous system, causing progressive damage to the spinal cord, peripheral nerves, and cerebellum. This leads to impaired muscle coordination, balance problems, and other neurological symptoms.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PTCT">PTCT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_12_18_34_PM_png_b76ebe8504.webp" alt="PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="61"><figcaption>PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock trading in the green despite the news.<stembedurl>https://stocktwits.com/deadlypants/message/625768448</stembedurl>TD Cowen analyst Joseph Thome lowered their price target on PTC Therapeutics to $50 from $56 while keeping a ‘Hold’ rating on the shares following the company’s update. The firm removed Friedreich's ataxia from its model and believes a second successful late-stage study will likely be required for approval.RBC Capital, which has an ‘Outperform’ rating and $63 price target on the stock, meanwhile, believes this was generally expected and already baked into the stock. The firm said that it would still buy the company's shares, according to TheFly.Jefferies analyst Kelly Shi also lowered the firm's price target on PTC Therapeutics to $63 from $64 while keeping a ‘Buy’ rating on the shares. The letter "didn't come in as a surprise to us," said the analyst, who calls the regulatory update "a clearing event" that allows investors to now focus on the launch of a treatment for phenylketonuria.&nbsp;PTCT stock is up by 14% this year and by about 50% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iovance-stock-rises-on-health-canada-approval-for-cancer-immunotherapy/chsgV4qRdW2">Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a PTC Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.

Equity

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.


PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Retail chatter around PTC Therapeutics surged Monday after the FDA approved Sephience (sepiapterin) for the treatment of phenylketonuria (PKU), a rare genetic disorder that disrupts the body’s ability to break down phenylalanine.&nbsp;The decision grants broad labeling for use in adults and children as young as one month who are responsive to sepiapterin.The approval was supported by results from the Phase 3 Aphenity trial and its long-term extension, which showed significant reductions in blood phenylalanine levels and sustained treatment effects.&nbsp;Sephience is designed to address hyperphenylalaninemia (HPA) across all PKU subtypes.The U.S. decision follows European Commission (EC) marketing authorization last month, which also granted a broad label across all ages and disease severities.&nbsp;PTC described the EC approval as a “great step” toward making Sephience available globally for patients with PKU.Analysts had been closely monitoring the regulatory timeline.&nbsp;Citi raised its price target on PTC Therapeutics to $50 from $40 earlier this month, adding a 30-day "upside catalyst watch" in anticipation of the FDA decision. The firm maintained a Neutral rating and noted it remains cautious about Sephience’s longer-term sales potential.On Stocktwits, retail sentiment for PTC Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/PTCT">PTC Therapeutics’ stock</a> has declined 3.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around PTC Therapeutics (PTCT) surged Monday after the FDA approved Sephience (sepiapterin) for the treatment of phenylketonuria. (Photo credit: Getty Images)

FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened

The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels.

Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.02	--	--	N/A
Q2 '25	-$1.02	-$0.83	18.74%	BEAT
Q1 '25	-$1.01	$10.04	1096.24%	BEAT
Q4 '24	-$0.54	-$0.85	-57.33%	MISSED
Q3 '24	-$1.52	-$1.39	8.63%	BEAT

PTCT
PTC Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest PTCT News

PTCT PTC Therapeutics Inc